- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| LONGEVERON Aktie jetzt für 0€ handeln | |||||
| Di | Longeveron Announces 2025 Full Year Financial Results and Provides Business Update | 814 | GlobeNewswire (Europe) | On track for third quarter 2026 top-line trial results from anticipated pivotal Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for HLHS, a rare pediatric... ► Artikel lesen | |
| Di | Longeveron Inc. - 10-K, Annual Report | 1 | SEC Filings | ||
| 12.03. | Longeveron Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 11.03. | Longeveron Announces Closing of Private Placement of up to $30 Million | 6 | GlobeNewswire (USA) | ||
| 11.03. | A $30 Million Reason to Buy Penny Stock Longeveron Today | 6 | Barchart.com | ||
| 10.03. | Longeveron secures $15M financing, eyes $15M more on trial results | 5 | Investing.com | ||
| 25.02. | Longeveron publishes phase 2b stem cell trial results in journal | 3 | Investing.com | ||
| 25.02. | Longeveron Results of Phase 2b Clinical Trial Demonstrating Stem Cell Therapy Improved Condition of Patients with Age-Related Frailty Published in Cell Stem Cell | 431 | GlobeNewswire (Europe) | MIAMI, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ: LGVN), a clinical stage biotechnology company developing regenerative cell therapy for life-threatening rare pediatric and chronic... ► Artikel lesen | |
| 13.02. | Longeveron ernennt Stephen Willard vor entscheidenden Studienergebnissen zum neuen CEO | 1 | Investing.com Deutsch | ||
| 13.02. | Longeveron appoints Stephen Willard as new CEO ahead of pivotal trial results | 2 | Investing.com | ||
| 13.02. | Longeveron Inc. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.02. | Longeveron Appoints Stephen H. Willard as Chief Executive Officer | 227 | GlobeNewswire (Europe) | Mr. Willard has a 30+ year track record of leadership across public and private sectors as CEO of multiple biotechnology and pharmaceutical firms, with an impressive history of delivering significant... ► Artikel lesen | |
| 13.02. | Longeveron appoints new CEO | 1 | Seeking Alpha | ||
| 05.02. | Longeveron Applauds Passage of the Mikaela Naylon Give Kids a Chance Act and Reauthorization of Rare Pediatric Disease Priority Review Voucher Program | 1 | GlobeNewswire (USA) | ||
| 29.01. | Longeveron Granted Japan Patent for Potency Assay Methods for Assessing Human Mesenchymal Stem Cells (MSCs) | 1 | GlobeNewswire (USA) | ||
| 26.01. | Longeveron prepares for pivotal HLHS therapy data with FDA meeting | 1 | Investing.com | ||
| 26.01. | Longeveron Announces FDA Grants Type C Meeting Ahead of Data Readout for Pivotal Phase 2 Clinical Trial (ELPIS II) Evaluating Treatment for Hypoplastic Left Heart Syndrome (HLHS) | 278 | GlobeNewswire (Europe) | ELPIS II top-line trial results are anticipated in the third quarter of 2026Laromestrocel Biological License Application (BLA) submission for full traditional approval for HLHS anticipated if ELPIS... ► Artikel lesen | |
| 29.12.25 | Longeveron, Selected as a StartUp Health Alzheimer's Disease Moonshot Company, Will Participate in StartUp Health Apollo House During JPM Healthcare Week 2026 | 5 | GlobeNewswire (USA) | ||
| 17.12.25 | Longeveron receives patent for stem cell therapy targeting female sexual dysfunction | 3 | Investing.com | ||
| 17.12.25 | Longeveron Granted U.S. Patent for Method of Treating Female Sexual Dysfunction Using its Proprietary Stem Cell Therapy | 1 | GlobeNewswire (USA) |
1 2 3 Weiter >>
47 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| CRISPR THERAPEUTICS | 40,000 | -0,99 % | Piper Sandler raises CRISPR Therapeutics price target on cash raise | ||
| OCUGEN | 1,983 | +2,30 % | Ocugen, Inc. - 8-K, Current Report | ||
| EDITAS MEDICINE | 2,018 | -0,74 % | Is Editas Medicine Going to $0? | ||
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,150 | -4,48 % | Canaccord reiterates Pacific Biosciences stock rating on new chemistry | ||
| DENALI THERAPEUTICS | 17,065 | -0,06 % | Denali Therapeutics Inc.: Denali Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights | Tividenofusp alfa (DNL310; ETV:IDS) launch readiness established ahead of April 5, 2026 Prescription Drug User Fee Act (PDUFA) target action date for Hunter syndromeDNL126 (ETV:SGSH) Phase 1/2 preliminary... ► Artikel lesen | |
| SOL GLOBAL INVESTMENTS | 0,048 | -7,69 % | SOL Global Investments Corp.: SOL Global Announces Leadership Transition and Grant of PSUs | Toronto, Ontario--(Newsfile Corp. - February 23, 2026) - SOL Global Investments Corp. (CSE: SOL) (FSE: 9SB) ("SOL Global" or the "Company"), today announced that Mr. Davide Marcotti has resigned... ► Artikel lesen | |
| TRINITY BIOTECH | 0,650 | 0,00 % | Trinity Biotech plc: Trinity Biotech Announces Collaboration with University at Buffalo to Commercialize Novel Biomarkers for Sjögren's Syndrome | ||
| FATE THERAPEUTICS | 0,957 | +3,17 % | Fate Therapeutics, Inc.: Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates | Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge Four systemic sclerosis... ► Artikel lesen | |
| VOYAGER THERAPEUTICS | 3,194 | -0,93 % | Voyager Therapeutics erklärt 2026 zum "Jahr des Tau" | ||
| ANAVEX LIFE SCIENCES | 3,904 | +8,05 % | Anavex Life Lead Drug Targets Early Alzheimer's Cause - New Study Highlights | ||
| ARCTURUS THERAPEUTICS | 6,730 | 0,00 % | Cathie Wood's ARK adds 10x Genomics stock, trims Arcturus | ||
| BIOAGE LABS | 18,200 | 0,00 % | AKTIONÄR-Tipp BioAge Labs wird entdeckt: 272 Prozent Kurspotenzial! | Der Megatrend Longevity hat nun auch die Aktie von BioAge Labs erfasst. Ausgehend vom 52-Wochen-Tief bei 2,88 Dollar konnte sich der Titel auf aktuell 19,60 Dollar zuletzt vervielfachen. Und die Analysten... ► Artikel lesen | |
| CERUS | 1,514 | -1,17 % | CERUS CORP - 8-K, Current Report | ||
| OVID THERAPEUTICS | 2,020 | +2,54 % | B.Riley bestätigt Kaufempfehlung für Ovid Therapeutics mit Kursziel von 5 US-Dollar | ||
| LINEAGE CELL THERAPEUTICS | 1,370 | +2,24 % | Regenerative Medizin im Aufbruch: NurExone Biologic, Regenxbio und Lineage Cell Therapeutics setzen auf unterschiedliche Zukunftstechnologien |
LONGEVERON INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 1,110 Euro und damit 0,00 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu LONGEVERON INC finden Sie auf Wallstreet Online.